公开(公告)号：US20160324844A1

公开(公告)日：2016-11-10

申请号：US14708276

申请日：2015-05-10

Applicant: Mythri Ambatipudi

Inventor： Mythri Ambatipudi

IPC: A61K31/455 ,  A61K31/375 ,  A61K31/355 ,  A61K31/352 ,  A61K31/353 ,  A61K31/417 ,  A61K31/05

CPC classification number: A61K31/455 ,  A61K31/05 ,  A61K31/352 ,  A61K31/353 ,  A61K31/355 ,  A61K31/375 ,  A61K31/4172 ,  A61K31/7004 ,  A61K31/7016 ,  A61K38/05 ,  A61K45/06 ,  A61K2300/00

Abstract: Methods for reducing the glycation of nutrient and endogenous proteins and methods for reducing the peroxidation of nutrient and endogenous lipids are provided herein. Several inhibitors and conditions of inhibiting glycation of nutrient and endogenous proteins and peroxidation of nutrient and endogenous lipids are also provided herein. Also provided are the methods for inhibiting and treating the conditions associated with the formation of glycated proteins, such as Alzheimer's disease, neuropathy, retinopathy and nephropathy and the methods for inhibiting and treating the conditions associated with the formation of peroxidized lipids, such as cancer and atherosclerosis.

Abstract translation: 本文提供了减少营养物和内源性蛋白质糖基化的方法以及减少营养物质和内源性脂质的过氧化作用的方法。 本文还提供了抑制营养物质和内源性蛋白质糖基化的抑制剂和条件以及营养物质和内源性脂质的过氧化作用。 还提供了用于抑制和治疗与形成糖基化蛋白质（诸如阿尔茨海默氏病，神经病变，视网膜病变和肾病）相关的病症的方法，以及用于抑制和治疗与形成过氧化脂质如癌症有关的病症的方法， 动脉粥样硬化。

公开(公告)号：US09481718B2

公开(公告)日：2016-11-01

申请号：US14691381

申请日：2015-04-20

Applicant: North American Hirudin Supplement Products Inc.

Inventor： Weiguan Zhou

IPC: A61K38/58 ,  A61K35/62 ,  C07K14/815 ,  C07K14/435 ,  A61K31/7016 ,  A61K31/7004 ,  A61K38/00

CPC classification number: C07K14/43536 ,  A61K31/7004 ,  A61K31/7016 ,  A61K38/00 ,  C07K14/815

Abstract: Described herein relates to methods and compositions for extracting hirudin from a plurality of leeches in vivo. The method may include contacting leeches with inducing membranes containing an inducing agent for a first predetermined time period. The inducing membranes may be removed from the leeches, and the leeches may be contacted with a regurgitation agent for a second predetermined time period in a container such that the leeches are induced to regurgitate regurgitation contents. The regurgitation contents may be collected and purified to obtain the hirudin.

Abstract translation: 本文涉及用于从体内从多个水蛭中提取水蛭素的方法和组合物。 该方法可以包括将水蛭与含有诱导剂的诱导膜接触第一预定时间段。 诱导膜可以从水蛭中去除，并且水蛭可以在容器中与反流剂接触第二预定时间段，使得水蛭被诱导回流反流内容物。 可以收集和纯化反流内容物以获得水蛭素。

公开(公告)号：US20160310578A1

公开(公告)日：2016-10-27

申请号：US15137654

申请日：2016-04-25

Applicant: Fuji Nihon Seito Corporation ,  Yutaka Research Institute

Inventor： Toshihiko INAGE ,  Tadashi WADA

IPC: A61K38/39 ,  A61K9/00 ,  A61K9/20 ,  A61K31/7048

CPC classification number: A61K38/39 ,  A23L33/10 ,  A23L33/15 ,  A23L33/16 ,  A23L33/17 ,  A23L33/18 ,  A23V2002/00 ,  A61K9/0053 ,  A61K9/2054 ,  A61K31/7016 ,  A61K45/06 ,  A61K2300/00

Abstract: A method for promoting osteogenesis including administering a therapeutically effective amount of collagen and a calcium absorption promoter to a subject.

Abstract translation: 一种用于促进成骨的方法，包括向受试者施用治疗有效量的胶原和钙吸收促进剂。

公开(公告)号：US09452180B2

公开(公告)日：2016-09-27

申请号：US14295154

申请日：2014-06-03

Applicant: Next21 K.K.

Inventor： Yuichi Tei ,  Nobuo Sasaki ,  Shigeki Suzuki

IPC: C07H3/04 ,  A61K31/7016 ,  A61K31/192 ,  A61K31/196 ,  A61K31/405 ,  A61K31/5415 ,  A61K31/616 ,  A61K45/06 ,  A61K47/26

CPC classification number: A61K31/7016 ,  A61K31/192 ,  A61K31/196 ,  A61K31/405 ,  A61K31/5415 ,  A61K31/616 ,  A61K45/06 ,  A61K47/26 ,  C07H3/04 ,  A61K2300/00

Abstract: A method of manufacturing a medical drug of alleviating damage of gastrointestinal mucosal induced by a non-steroidal anti-inflammatory drug, NSAID, the medical drug being able to induce anti-inflammatory effect of the NSAID and being able to alleviate damage induced by the NSAID includes dissolving trehalose and the NSAID into one or more solutions, so as to obtain an approximately homogenously-mixed liquid mixture of the trehalose and the NSAID; in which the liquid mixture contains an intermolecular compound with the trehalose and the NSAID; and drying the liquid mixture so as to obtain the medical drug.

Abstract translation: 一种减轻由非甾体抗炎药物NSAID引起的胃肠粘膜损伤的药物的制造方法，所述药物能够诱导NSAID的抗炎作用并且能够减轻NSAID诱导的损伤 包括将海藻糖和NSAID溶解在一种或多种溶液中，以获得海藻糖和NSAID的近似均匀混合的液体混合物; 其中液体混合物含有与海藻糖和NSAID的分子间化合物; 并干燥该液体混合物以获得该药物。

公开(公告)号：US09446058B2

公开(公告)日：2016-09-20

申请号：US12921383

申请日：2008-03-04

Applicant: Aleksander Vladimirovich Dikovskiy ,  Boris Anatolievich Rudoy ,  Oleg Valentinovich Dorozhko

Inventor： Aleksander Vladimirovich Dikovskiy ,  Boris Anatolievich Rudoy ,  Oleg Valentinovich Dorozhko

IPC: A01N43/04 ,  A61K31/715 ,  A61K31/66 ,  A23L1/30 ,  A23L1/308 ,  A61K31/685 ,  A61K36/28 ,  A61K45/06 ,  A61K31/702 ,  A61K31/7016

CPC classification number: A61K31/575 ,  A23L33/10 ,  A23L33/21 ,  A23V2002/00 ,  A61K9/0053 ,  A61K31/52 ,  A61K31/66 ,  A61K31/685 ,  A61K31/7016 ,  A61K31/702 ,  A61K36/28 ,  A61K45/06 ,  A61K2300/00 ,  A23V2250/28 ,  A23V2200/3202 ,  A23V2200/32 ,  A23V2250/1842 ,  A23V2250/5046

Abstract: The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelitiasis mainly with cholesterol stones, alcoholic and non-alcoholic steatohepatitis, biliary cirrhosis, cholesterol imbibition gallbladder and drug-induced and toxic liver damage. The pharmaceutical composition is administered by mouth and contains a hepatoprotector and a prebiotic taken, as an active agent, in therapeutically effective doses. The invention contributes to the liver's functional recovery in a short time and prevents disease recidivation owing to the recovery of cholesterol exchange and intestinal biocenosis as a result of the synergistic interaction of a hepatoprotector and a prebiotic, thereby also preventing hepatoprotector side effects.

Abstract translation: 本发明涉及药物，肝脏和药理学，可用于制备和使用基于肝保护剂和益生元的药物组合物，用于治疗和预防由脂质 - 胆固醇交换引起的肝脏疾病，并且选自以下组：胆汁淤积主要 胆固醇结石，酒精和非酒精性脂肪性肝炎，胆汁性肝硬化，胆固醇吸收胆囊和药物诱发和毒性肝损伤。 药物组合物通过口服给药，并含有作为活性剂的肝脏保护剂和益生元，其具有治疗有效剂量。 本发明在短时间内有助于肝脏的功能恢复，并且由于肝保护剂和益生元的协同相互作用，由于胆固醇交换和肠内生物死亡的恢复而防止疾病复发，从而也防止肝脏保护剂的副作用。

公开(公告)号：US20160250242A1

公开(公告)日：2016-09-01

申请号：US15153962

申请日：2016-05-13

Applicant: OPKO Health, Inc.

Inventor： Tahir AHMED

IPC: A61K31/7016 ,  A61K9/00 ,  A61K47/32

CPC classification number: A61K31/7016 ,  A61K9/0053 ,  A61K47/32

Abstract: Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The compounds are formulated with agents that enhance the oral delivery of the hypersulfated disaccharides. The delivery agents are selected from the group consisting of natural or synthetic polymers having ionic side chains as well as other compounds or types of compounds that improve the bioavailability of the disaccharides relative to delivery of the drug without such agents. The hypersulfated disaccharides are made from heparin or salts thereof.

公开(公告)号：US09421226B2

公开(公告)日：2016-08-23

申请号：US14414735

申请日：2013-07-18

Applicant: Heat Sport Sciences, Inc.

Inventor： Arthur R. Bartolozzi ,  Sandra Fowkes Godek

IPC: A61K33/20 ,  A61K33/14 ,  A61K31/047 ,  A61K31/70 ,  A61K31/7016 ,  A61K9/00 ,  A23L1/304 ,  A23L2/39 ,  A61K31/7004 ,  A61K33/00

CPC classification number: A61K33/20 ,  A23L2/39 ,  A23L33/16 ,  A61K9/0095 ,  A61K31/047 ,  A61K31/70 ,  A61K31/7004 ,  A61K31/7016 ,  A61K33/00 ,  A61K33/14 ,  A61K2300/00

Abstract: The present invention provides methods for maintaining electrolyte balance and hydration in a person habituated to strenuous physical exertion by assaying perspiration generated by the person under conditions of strenuous physical exertion to determine the volume of perspiration as a function of duration of exertion and the sodium content of the person's perspiration during strenuous physical exertion The person is assigned to one of a plurality of groups of individuals, each group differing in the amount of sodium present in the perspiration and having a unique rehydration solution. The invention also provides for a set rehydration compositions, each member of the set comprising sodium and chloride differing from the weight percentage of sodium in the other members of the set and each member of the set being perceptually labeled to distinguish that member from the other members of the set by one of the human senses.

Abstract translation: 本发明提供了通过测定在剧烈的体力劳动条件下由人产生的汗液来确定作为使用持续时间的函数的排汗量和钠含量的方法来维持患有剧烈体力消耗的人的电解质平衡和水合的方法 该人在剧烈体力劳动期间的汗水该人被分配到多组个体中的一组，每组在出汗中存在钠量不同，并且具有独特的补液解决方案。 本发明还提供了一种设定的补液组合物，该组的每个成分包含钠和氯化物，其不同于该组的其它成员中的钠的重量百分比，并且该组的每个成员被感知地标记以将该成员与其他成员区分开 由人的感官之一组成。

公开(公告)号：US20160193275A1

公开(公告)日：2016-07-07

申请号：US14912339

申请日：2014-08-15

Applicant: THE PRODUCT MAKERS (AUSTRALIA) PTY LTD.

Inventor： Leodevico Luna Ilag ,  Timothy Peter Ellis ,  Alison Grace Wright

IPC: A61K36/899 ,  A61K31/7004 ,  A61K31/7016

CPC classification number: A61K36/899 ,  A23L2/52 ,  A23L33/105 ,  A61K31/05 ,  A61K31/7004 ,  A61K31/7016 ,  A61K2300/00

Abstract: The invention relates to extracts produced from sugar cane processing stream products having desirable properties and health benefits. More particularly the invention relates to sugar cane derived extracts obtained from molasses, methods of producing the extracts, and uses of the extracts for management of insulin resistant conditions or subjects predisposed to such conditions, such as type 2 diabetes. The sugar cane derived extracts of the invention are enriched in polyphenols and the administration of the sugar cane derived extract regulates postprandial glucose response and insulin response and lowering those responses, to avoid the subject becoming hypoglycaemic.

Abstract translation: 本发明涉及由具有所需性质和健康益处的甘蔗加工流产品生产的提取物。 更具体地，本发明涉及从糖蜜获得的甘蔗衍生的提取物，生产提取物的方法，以及用于管理胰岛素抗性病症或倾向于这种病症的受试者例如2型糖尿病的用途。 本发明的甘蔗衍生的提取物富含多酚，并且甘蔗衍生的提取物的施用调节餐后葡萄糖反应和胰岛素反应并降低这些应答，以避免受试者变得低血糖。

公开(公告)号：US20160175393A1

公开(公告)日：2016-06-23

申请号：US15057324

申请日：2016-03-01

Applicant: N.V. NUTRICIA

Inventor： Renate Maria Louise ZWIJSEN ,  Gunther BOEHM

IPC: A61K38/17 ,  A61K31/202 ,  A61K31/14 ,  A61K31/702 ,  A61K31/688 ,  A61K31/575 ,  A61K31/201 ,  A61K31/7016

CPC classification number: A61K38/1709 ,  A23L33/12 ,  A23L33/125 ,  A23L33/40 ,  A23V2002/00 ,  A61K31/14 ,  A61K31/185 ,  A61K31/198 ,  A61K31/20 ,  A61K31/201 ,  A61K31/202 ,  A61K31/575 ,  A61K31/688 ,  A61K31/7016 ,  A61K31/702 ,  A61K35/20 ,  A23V2250/1882 ,  A23V2250/1878 ,  A23V2250/54246 ,  A23V2250/612 ,  A23V2250/28 ,  A23V2250/1846

Abstract: A nutritional composition comprising phospholipids, sphingolipids and cholesterol for the prevention of obesity and/or diabetes is provided.

Abstract translation: 提供了包含用于预防肥胖和/或糖尿病的磷脂，鞘脂和胆固醇的营养组合物。

公开(公告)号：US09370532B2

公开(公告)日：2016-06-21

申请号：US14485301

申请日：2014-09-12

Applicant: RITTER PHARMACEUTICALS, INC.

Inventor： Andrew J. Ritter ,  Dennis Savaiano ,  David Barnes ,  Todd Klaenhammer

IPC: C12P19/04 ,  A61K35/20 ,  C12P1/04 ,  A61K31/715 ,  A23L1/308 ,  A61K31/702 ,  A61K35/745 ,  A61K35/747 ,  A61K31/7016 ,  A61K35/741 ,  A61K9/48

CPC classification number: A61K31/715 ,  A23L33/135 ,  A23L33/21 ,  A23V2002/00 ,  A23Y2220/00 ,  A23Y2300/00 ,  A61K9/4825 ,  A61K31/7004 ,  A61K31/7016 ,  A61K31/702 ,  A61K35/741 ,  A61K35/745 ,  A61K35/747 ,  Y02A50/473 ,  A61K2300/00 ,  A23V2200/32 ,  A23V2200/3202 ,  A23V2200/3204

Abstract: The invention provides methods and compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolerance by administering to subject in need thereof a prebiotic composition, optionally in combination with effective amount of a probiotic microbe or microbes.